GO
Loading...

Bristol-Myers Squibb Co

More

  • Lightning Round: Potash, GameStop & more Tuesday, 10 Jun 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites

  • Investors eye Achillion for next big pharma deal Tuesday, 10 Jun 2014 | 2:20 PM ET
    Achillion web page

    Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago.

  • Why Merck's Idenix deal is bad news for Gilead Monday, 9 Jun 2014 | 2:34 PM ET

    Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • ZURICH, June 2- Roche is betting the same tools that made it the world's largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research.

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • CHICAGO, June 1- U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co on patients newly diagnosed with the most common form of deadly brain tumors in adults.

  • Immuno-what? How these cancer therapies work Thursday, 29 May 2014 | 12:27 PM ET
    Laboratory which develops therapeutic vaccinations to treat cancer.

    A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?

  • May 28- German drugmaker Boehringer Ingelheim said on Wednesday it would pay about $650 million to settle U.S. lawsuits that claimed the company's blockbuster blood thinner, Pradaxa, had caused severe and fatal bleeding in patients.

  • May 28- German drugmaker Boehringer Ingelheim said it would pay about $650 million to settle U.S. lawsuits that claimed the company's blockbuster blood thinner Pradaxa had caused severe and fatal bleeding in patients.

  • COPENHAGEN, May 28- Danish drugmaker Novo Nordisk, the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug Tresiba in Germany on May 1 after seeing signs of a more favourable pricing situation there.

  • Why Pfizer should try to buy Bristol-Myers Tuesday, 27 May 2014 | 1:21 PM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    What's next for Pfizer, now that its bid for AstraZeneca has been laid to rest, at least temporarily. Analysts weigh in with their views.

  • How AstraZeneca escaped Pfizer clutches...this time Tuesday, 27 May 2014 | 8:20 AM ET

    Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.

  • AstraZeneca free for now as May 26 deadline passes. LONDON, May 27- On a sunny day in San Francisco last January, AstraZeneca Chief Executive Pascal Soriot was on his way to the Westin St. Francis hotel on Union Square to give investors some unexpectedly good news.

  • Why there's no end in sight for higher drug costs Thursday, 22 May 2014 | 7:06 AM ET
    About 40 protesters from across the country converged on Gilead Sciences headquarters in Foster City, Calif., Nov. 14, 2012, calling on the drug maker to lower prices for its Stribild AIDS medication.

    The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.

  • The latest salvo in the war on escalating U.S. healthcare costs came from AHIP- America's Health Insurance Plans- and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc..

  • May 20- The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.